Featured Editorial

1. Engineering Better ADCs, Part 1: MoA, Conjugation Chemistry, And More 9/24/2026

   The field has evolved considerably in antibody–drug conjugate (ADC) science. In this first article of a two-part series, let's discuss how to engineer better ADCs, covering MoA, conjugation chemistry, and more.

2. From Albumin To Oncology: Can Chemical Engineering Unlock Solid Tumor Delivery? 9/23/2026

   We discuss how selective albumin binding improved tumor delivery in preclinical studies and what these findings could mean for the future of siRNA-based cancer therapies.

3. A Practical Framework For Selecting Long-Acting Injectable Platforms Across Therapeutic, Product, And Delivery Constraints 9/22/2026

   Platform selection for long-acting injectables is increasingly complex because therapeutic modalities, delivery systems, and target product expectations have all diversified. Can your selected platform meet the needs of your product?

4. Using Low-Intensity Focused Ultrasound To Open The Blood–Brain Barrier 9/11/2026

   We caught up with Davinder Ramsingh, MD, to talk about the potential of using low-intensity focused ultrasound (LIFU) to open the blood–brain barrier.

5. Engineering Medical Devices To Improve Oral Delivery Of Biopharmaceuticals 9/10/2026

   Two approved GLP-1 pills validated the demand — and exposed the ceiling that only delivery devices can break.

6. Oral Combination Therapies: Navigating Development Complexities 9/10/2026

   We discuss how delivery strategy influences development decisions, learnings from advancing IHL-42X, and Latham's perspective on the future of patient-centric drug delivery.

7. Beyond GalNAc: Reengineering siRNA For Extrahepatic Delivery 9/9/2026

   We discuss why effective extrahepatic delivery remains one of the field's biggest obstacles and how chemical engineering may provide a new path forward.

8. Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases 9/4/2026

   Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition. 

9. The Future Of Cancer Drug Discovery Is Targeted Immune Activation 9/2/2026

   Using targeted delivery systems to generate therapeutic agents directly within tumors has implications for how oncology drugs are discovered and developed.

10. Part 4 cGMP Summaries For Combination Products: Uncovering FDA Expectations 9/1/2026

    In this article, consultant Doug Mead reports on precedent research he conducted into FDA databases on 21 CFR Subpart cGMPs for combination products. His observations and conclusions offer sound advice on how to approach summaries submitted for BLA and NDA purposes.